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Abstract 24
The brush border Cl --oxalate exchanger SLC26A6 plays an essential role in mediating 25 intestinal secretion of oxalate, and is crucial for the maintenance of oxalate homeostasis 26 and the prevention of hyperoxaluria and calcium oxalate nephrolithiasis. Previous in 27 vitro studies have suggested that SLC26A6 is heavily N-glycosylated. N-linked 28 glycosylation is known to critically affect folding, trafficking and function in a wide variety 29 of integral membrane proteins and could therefore potentially have a critical impact on 30 SLC26A6 function and subsequent oxalate homeostasis. Through a series of 31 enzymatic deglycosylation studies we confirmed that endogenously expressed mouse 32 and human SLC26A6 are indeed glycosylated, that the oligosaccharides are principally 33 attached via N-glycosidic linkage, and that there are tissue-specific differences in 34 glycosylation. In vitro cell culture experiments were then used to elucidate the functional 35 significance of the addition of the carbohydrate moieties. Biotinylation studies of 36 SLC26A6 glycosylation mutants indicated that glycosylation is not essential for cell 37 surface delivery of SLC26A6, but suggested that it may affect the efficacy with which it 38 is trafficked and maintained in the plasma membrane. Functional studies of transfected 39 SLC26A6 demonstrated that glycosylation at two sites in the putative second 40 extracellular loop of SLC26A6 are critically important for chloride-dependent oxalate 41 transport, and that enzymatic deglycosylation of SLC26A6 expressed on the plasma 42 membrane of intact cells strongly reduced oxalate transport activity. Taken together, 43 these studies indicated that oxalate transport function of SLC26A6 is critically 44 dependent on glycosylation, and that exoglycosidase mediated deglycosylation of 45 SLC26A6 has the capacity to profoundly modulate SLC26A6 function. 46
INTRODUCTION 50
SLC26A6 is an anion exchanger that is expressed on the apical membrane of 51 several epithelial tissues including intestinal mucosa (20, 23, 33 (7, 8, 19, 34) . Studies using Slc26a6-null mice have demonstrated that 55 SLC26A6 plays an essential role in mediating intestinal secretion of oxalate (9, 18) . 56
Slc26a6 knockout mice have enhanced net absorption of dietary oxalate, resulting in 57 hyperoxalemia, hyperoxaluria, and increased risk for calcium oxalate urolithiasis (9, 18, 58 26). Thus, intestinal oxalate secretion mediated by SLC26A6 plays a crucial role in 59 limiting net absorption of ingested oxalate, thereby preventing hyperoxaluria and 60
urolithiasis. 61
N-linked glycosylation is the most commonly identified form of carbohydrate 62 addition in SLC family solute transporters (28). Glycosylation has been shown to 63 critically affect trafficking and function of several SLC transporters including the SLC12 64 cation-chloride cotransporters NCC and NKCC2 (16, 27) , the SLC14 urea transporters 65 UT-A1 and UT-A3 (5, 6), and several members of the SLC26 family (2, 15, 25) . 66
Study of the glycosylation of SLC26A6 is of interest because of the potential for 67 glycosylation to modify SLC26A6 function and thereby influence oxalate homeostasis 68 and the propensity for urolithiasis. In fact, it has been demonstrated by use of site-69 directed mutagenesis that SLC26A6 overexpressed by transfection of HEK cells is N-70 glycosylated at asparagine residues 167 and 172 and that glycosylation affects surface 71 membrane expression of SLC26A6 (21). But it has not previously been determined if 72 TTGGATCATGGAGTCTTGCAAGGCCTGCGGGGC-3'). All constructs were confirmed 131 by restriction analysis and cDNA sequencing (Yale Keck DNA sequencing facility SLC26A6 regulation (13, 14) . The uptake protocol was designed to 171 specifically evaluate the chloride-dependent component of in mouse kidney compared to duodenum and jejunum indicated that the degree of 210 glycosylation is markedly tissue specific. Given that the treatment with the N-linkage-211 specific glycosidase PNGase F alone resulted in the same molecular weight shift as that 212 observed with a broad-specificity glycosidase cocktail, the glycopeptide linkages 213 observed in both mouse and human isoforms of SLC26A6 are primarily via N-glycosidic 214 bonding. It may be noted in Figure 2 that there was heterogeneity of apparent 215 molecular weight of SLC26A6 remaining after deglycosylation. This heterogeneity could 216 reflect differences in other post-translational modifications such as phosphorylation, or 217 reflect the expression of splice isoforms (7, 24, 34) . (1) and is, 226 therefore, an unlikely candidate for glycosylation. 227
Using site-directed mutagenesis, Li et al (21) reported that SLC26A6 transiently 228 transfected into HEK cells was glycosylated at residues 167 and 172. To confirm that 229 observation and to determine the functional significance of glycosylation at each of 230 these sequons we generated a series of Asn to Gln hSLC26A6 mutants (167-N/Q-hA6, 231
172-N/Q-hA6, and 167+172-N/Q-hA6). The constructs were transiently transfected into 232 OKP cells and the resultant expression profiles of the mature glycoforms of the 233 SLC26A6 variants were monitored by Western analysis with antibodies directed against 234 human SLC26A6. We restricted our analysis to the mature glycoforms of the respective 235 constructs by performing Western analysis on cell surface biotinylated proteins only. 236
The apparent molecular weight of mature transfected wild-type hSLC26A6 (wt-237 hA6; Figure 3 ) was similar to that observed earlier in CaCo2b cells and mouse intestine 238 clearly illustrates that glycosylation is not essential for plasma membrane delivery of 253
SLC26A6. 254
We next addressed the possibility that while glycosylation may not be essential 255
for cell surface expression of SLC26A6, it may influence the efficacy of its surface 256 delivery. We therefore performed a comparative quantitative analysis of cell surface 257 biotinylation relative to total protein expression for OKP cells transiently transfected with 258 either wt-hA6 or 167+172-N/Q-hA6 ( Figure 5 ). In these studies similar amounts of DNA 259 were used to transfect each expression construct and for comparative purposes 10% of 260 each total lysate was loaded in each respective "lysate" gel lane (Figure 5a ) and 90% of 261 the biotinylatable fraction was loaded in each respective "biotinylated" gel lane (Figure  262 5b). Transfection with 167+172-N/Q-hA6 resulted in consistently less biotinylatable 263 SLC26A6 being delivered to the plasma membrane than that observed with transfection 264 of the wild-type construct (Figure 5d) . Interestingly, the lower surface expression of 265 mutant compared to wild-type SLC26A6 contrasted with the finding that the total cellular 266 expression level of mutant was higher than that of wild-type SLC26A6 (Figure 5c From our earlier studies it was clear that glycosylation significantly affected the 287 delivery of SLC26A6 to the plasma membrane. To determine if the glycosylation-288 dependent transport effect that we were observing was partially a consequence of 289 reduced transporter expression on the plasma membrane rather than an actual 290 decrease in the transport capacity of the expressed proteins per se, we simultaneously 291 were then used to normalize the 14 C-oxalate uptake data. Using this approach we 296 observed a corrected mean decrease in transport of 69%, suggesting that a minor 297 portion of the decrease could be attributed to a decrease in cell surface delivery of 298 SLC26A6 and that most of the decrease in transport was due to an intrinsic change in 299 the ability of the protein to mediate chloride-oxalate exchange. It must be 300 acknowledged, however, that this calculation is based on the assumption that 301 biotinylation and transfer of wild-type and mutant SLC26A6 have identical efficiency, 302 which are not known with certainty. Nevertheless, the conclusion that glycosylation 303 strongly affects intrinsic transport activity independent of surface expression was 304 subsequently supported by studies of enzymatic deglycosylation of surface SLC26A6 305 (see below). 306 N-linked glycosylation is known to play a crucial role in both folding and quality 307 control of proteins transiting through the early biosynthetic pathway enroute to the 308 plasma membrane (32). It is therefore possible that the glycosylation-dependent 309 transport effect that we observed above may have been due to plasma membrane 310 We have clearly demonstrated that endogenously expressed human and mouse 329 SLC26A6 are similarly heavily glycosylated, and that the carbohydrate moieties are 330 principally attached to the polypeptide backbone of SLC26A6 via N-glycosidic linkage. 331
While it is possible that some O-glycosidic linkages may be refractory to a simple digest 332 with the O-glycosidase cocktail utilized in this study, the extensive molecular weight shift 333 that we observed with PNGase F alone to approximately 65 kDa compared to the 334 predicted unmodified molecular weight of 83 kDa for both human and mouse SLC26A6 335 (UniProtKB Q9BXS9-1 and Q8CIW6-1 respectively) makes it highly unlikely that a 336 significant fraction of SLC26A6 glycosylation in either human or mouse has an O-linked 337
component. 338
An unexpected finding in this study is the markedly tissue-specific glycosylation 339 of SLC26A6. SLC26A6 expressed endogenously in mouse kidney had a consistently 340 lower apparent molecular weight than that observed for SLC26A6 in either the 341 duodenum or the jejunum. Digest of SLC26A6 in all three tissues with PNGase F 342 resulted in identical post-digest apparent molecular weights, indicating that the original 343 molecular weight disparity was likely due to a difference in glycosylation and not other 344 unidentified post-translational modifications or alternative splicing. The existence of 345 multiple glycoforms of SLC26A6 raises the possibility that carbohydrate composition 346 may influence SLC26A6 function and regulation as has been reported for the renal urea 347 transporter, UT-A1. In the renal medulla, UT-A1 is comprised of two distinct glycoforms 348 that are differentially regulated in response to imposed urea loads and altered urea 349 transport requirements (4). 350
We have confirmed that transfected human SLC26A6 is capable of being 351 glycosylated via N-glycosidic linkage at the sequons located at amino acids 167 and 352 172 located within the putative second extracellular loop of SLC26A6 as reported by Li 353 et al (21) . Moreover, we have demonstrated that SLC26A6 mutated at these two sites 354
does not shift molecular weight after PNGase F treatment, indicating the absence of 355 additional sites of N-glycosylation. We demonstrated that our in vitro expression 356 system resulted in glycosylation of transfected human SLC26A6 in a pattern and to an 357 extent similar to that observed for endogenously expressed human SLC26A6 in Caco2b 358 cells. Under these conditions, glycosylation was clearly not essential for cell-surface 359 delivery of SLC26A6, but it did appear to significantly affect the efficiency with which the 360 transfected protein was expressed on the plasma membrane, consistent with a potential 361 role in membrane trafficking and/or protein stabilization. 362
The lack of an obligate glycosylation requirement for the membrane targeting of 363 transfected SLC26A6 is somewhat surprising given the well established role for N-364 glycosylation in membrane protein biosynthesis and trafficking (32), but it is consistent 365 with published results of glycosylation studies with other members of the SLC26 family 366 (2, 15, 21, 25). It should be noted, however, that in all of these studies this question was 367 similarly addressed by exogenous overexpression of SLC26 glycosylation mutants. It is 368 well known that substantial overexpression of a protein of interest can result in 369 artifactual processing and trafficking and that the resultant in vitro expression patterns 370 can be very different from what is observed in vivo (12). We were aware of this 371 potential problem at the outset of our study and intentionally scaled back the amount of 372 DNA used for all transfections in an attempt to limit the overexpression of SLC26A6 and 373 any possible attendant trafficking artifacts. Nevertheless, the possibility still remains 374 that the surface expression of mutant nonglycosylated SLC26A6 that we observed is 375 the result of overexpression. 376
We have demonstrated that beyond a basic requirement of glycosylation for 377 efficient surface expression, glycosylation of human SLC26A6 at sequons 167 and 172 378 is critically important for chloride-dependent oxalate transport activity. Prevention of 379 glycosylation of SLC26A6 by mutagenesis, or deglycosylation by cell treatment with 380 external PNGase F, both resulted in comparable levels of inhibition of transport. These 381 findings taken together indicate that glycosylation at sequons 167 and 172 is important 382 for oxalate transport function of SLC26A6. Reports of similar direct effects of 383 glycosylation on transport function of SLC family members are relatively uncommon, 384 and the exact mechanisms by which glycosylation directly influences SLC transporter 385 function remain largely uncertain (see Pedersen et al (28) for an extensive review). 386
The observation that enzymatic deglycosylation of SLC26A6 expressed on the 387 plasma membrane of intact cells reduced oxalate transport activity by approximately 388 50% suggests that SLC26A6 function could be modified by exposure to luminal 389 glycosidase activity under physiological or pathological conditions. For example, in the 390 kidney the apical membrane abundance of the TRPV5 Ca 2+ channel has been shown to 391 be directly modulated through the putative glycosidase activity of secreted Klotho (3). 392
The PNGase F digest data also illustrate the ease with which native SLC26A6 function 393 could potentially be compromised, particularly in the bowel, by disease states that 394 facilitate exposure to foreign exoglycosidases (30). The intestine of patients with cystic 395 fibrosis, for example, typically has very poor mucociliary clearing and is extremely 396 susceptible to bacterial overgrowth (10, 22) . Patients with cystic fibrosis are known to 397 have increased incidence of hyperoxaluria and attendant calcium oxalate nephrolithiasis 398 (11, 17) . It is therefore possible that exposure of SLC26A6 to elevated levels of 399 bacterial exoglycosidase activity could inhibit intestinal oxalate secretion and thereby 400 contribute to hyperoxalemia, hyperoxaluria and calcium oxalate nephrolithiasis in 401 patients with cystic fibrosis. 402
In conclusion, we have demonstrated that endogenously expressed human and 403 mouse SLC26A6 is heavily glycosylated and that in both species the carbohydrate 404 moieties are attached principally via N-glycosidic linkage. We have also found that 405 SLC26A6 is glycosylated in a tissue-specific manner in vivo, raising the possibility that 406 glycosylation may mediate tissue-specific regulation of function of SLC26A6. Although 407 we did not find that glycosylation is essential for plasma membrane targeting of human 408 
